Paper Review Records
All Paper Review Records
17 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
145
days
TREM2 c·3G>A promotes aberrant microglial-endothelial signaling, impairs BBB integrity, and enhances Aβ and Tau accumulation
Authors
Han-Chen Yang; Christabel Xin Tan; Ouyang Chen; Jing Zhang; Yu-Sen Deng; Zhibin Wang; Liwei Sun; Ye Liang; Yusheng Wei; Yunsi Yin; Yuhang Zhang; Bao-Dong He; Rui-Yang Li; Run Di; Chuheng Jiang; Meng Wang; Zhi-Qing David Xu; Chang-Mei Liu; Yi Xing; Chunlin Li; Qi Qin; Zhao-Qian Teng; Yi TangShow moreShow less
Affiliations
1. Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China; 2. Beijing Key Laboratory of Digital Medicine for Cognitive Disorders, Beijing, China; 3. Chinese Institute for Brain Research, Beijing, China; 4. State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China; 5. Life Sciences Institute, University of Michigan, Ann Arbor, USA; 6. School of Biomedical Engineering, Beijing Key Laboratory of Fundamental Research on Biomechanics in Clinical Application, Capital Medical University, Beijing, China; 7. Core Facility of the State Key Laboratory of Membrane Biology, Peking University, Beijing, China; 8. College of Life Sciences, Peking University, Beijing, China; 9. Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, ChinaShow moreShow less
125
days
Revealing white matter hyperintensities-related faster posterior cortical tau accumulation in Alzheimer’s Disease
Authors
Yue Cai; Jie Yang; Chao Huang; Li Liang; Lili Fang; Xin Zhou; Wei Liu; Pan Sun; Anqi Li; Mingxu Li; Zhengbo He; Yalin Zhu; Yiying Wang; Yu Wang; Chenfei Ye; Zhen Liu; Minjie Tan; Ting Ma; Ying Han; Tengfei GuoShow moreShow less
Affiliations
1. Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China; 2. Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China; 3. Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, China; 4. State Key Laboratory of Digital Medical Engineering, Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Sanya, China; 5. School of Electronic and Information Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen, China; 6. Division of Life Science, The Hong Kong University of Science and Technology, Kowloon, China; 7. Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; 8. School of Life Science and Technology, Harbin Institute of Technology, Harbin, China; 9. MRI R&D, Neusoft Medical Systems Co., Ltd., Shanghai, China; 10. School of Biomedical Engineering, Harbin Institute of Technology (Shenzhen), University Town, Shenzhen, China; 11. Department of Neurology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China; 12. Department of Geriatrics of Changji People’s Hospital, Changji, ChinaShow moreShow less
243
days
SALL1 as a marker for distinguishing microglia from blood-derived myeloid cells in stroke brain scRNA-seq data
Authors
Chu-Yan Zhang; Yi-Ming Lu; Heng Zhang; Yi-Sheng Li; Luo-Yi-Fan He; Yi-Yao Gao; Mu-Zhou Xue; Zi-Yu Wang; Zi-Bo Tang; Li-Li Feng; Jiali Wang; Yi-Xuan ZhangShow moreShow less
Affiliations
1. Medical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, China, School of Pharmacy, Nanjing Medical University, Nanjing, China; 2. Department of Hematology and Oncology, Children’s Hospital of Nanjing Medical University, Nanjing, China; 3. Children’s Hospital of Nanjing Medical University, Nanjing, China; 4. International Joint Laboratory for Drug Target of Critical Illnesses, School of Pharmacy, Nanjing Medical University, Nanjing, China; 5. Northern Jiangsu Institute of Clinical Medicine, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaShow moreShow less
183
days
In vivo detection of pathologic α- synuclein and TDP-43 in the skin and olfactory mucosa of a patient with Parkinson’s disease-like phenotype carrying the p.Thr272Serfs*10 GRN mutation
Authors
Paola Caroppo; Vittoria Aprea; Cristina Villa; Ilaria Linda Dellarole; Aurora Romeo; Giacomina Rossi; Arianna Ciullini; Anna Burato; Sara Prioni; Marina Grisoli; Giuseppe Legname; Giulia Simmini; Alessia Luppino; Samanta Mazzetti; Fabio Moda; Grazia DevigiliShow moreShow less
Affiliations
1. Neurology 8 – Dementia and Degenerative Diseases of CNS Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 2. SSD Laboratory Medicine-Laboratory of Clinical Pathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 3. Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore Di Studi Avanzati (SISSA), Trieste, Italy; 4. Clinical Neuropsychology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 5. Neuroradiology Unit – Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 6. Neurology 1 Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 7. Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, ItalyShow moreShow less
62
days
Dynamic [ 18 F]PI-2620 recording facilitates prediction of β-amyloid positivity and simultaneous staging of tau and neurodegeneration
Authors
Johannes Gnörich; Julia Kusche-Palenga; Agnes Kling; Amir Dehsarvi; Angela Bronte; Lukas Frontzkowski; Artem Zatcepin; Mirlind Zaganjori; Florian Schöberl; Sebastian N. Roemer-Cassiano; Boris-Stephan Rauchmann; Carolin Kurz; Carla Palleis; Alexander M. Bernhardt; Alexander Jäck; Sabrina Katzdobler; Maximilian Scheifele; Theresa Bauer; Gérard N. Bischof; Thilo van Eimeren; Alexander Drzezga; Jan Häckert; Robert Perneczky; Michael Rullmann; Katharina Buerger; Rudolf A. Werner; Andreas Zwergal; Johannes Levin; Peter Bartenstein; Osama Sabri; Henryk Barthel; Sophia Stöcklein; Günter Höglinger; Nicolai Franzmeier; Matthias BrendelShow moreShow less
Affiliations
1. Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany; 2. German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; 3. Institute for Stroke and Dementia Research, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany; 4. Universidad de Navarra, Pamplona, Spain; 5. Department of Neurology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany; 6. Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany; 7. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; 8. Department of Nuclear Medicine, Faculty of Medicine, University Hospital Cologne, Cologne, Germany; 9. Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; 10. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; 11. Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany; 12. Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK; 13. Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK; 14. Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; 15. The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine, Johns Hopkins School of Medicine, Baltimore, USA; 16. German Center for Vertigo and Balance Disorders, DSGZ, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany; 17. Department of Radiology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany; 18. The Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal and Gothenburg, SwedenShow moreShow less
160
days
Retromer-targeted therapy for neurodegenerative diseases
Authors
Michele Persico; Sophronea Tuithung; Alejandra Lorenzo; Darynaisha Crawford; Simona Eleuteri; David K. SimonShow moreShow less
Affiliations
1. Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA; 2. Department of Neurology, Emory University School of Medicine, Atlanta, USAShow moreShow less
FAQ
How long does Molecular Neurodegeneration take to review a manuscript?
As of 2026-11-18, CrushSCI has 17 complete review records for Molecular Neurodegeneration. The fastest paper went from submission to acceptance in 39 days (Breaking the glial loop: astrocytic PAD2 and citrullinated vimentin drive microglial dysfunction in Alzheimer’s disease, received 2026-05-28, accepted 2026-07-06); the slowest took 243 days. The average is 136.1 days and the median is 128 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
